Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

MABE333

Sigma-Aldrich

Anti-N-Myc Antibody, clone NCM II 100

clone NCM II 100, from mouse

Sinónimos:

N-myc proto-oncogene protein, Class E basic helix-loop-helix protein 37, bHLHe37

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Código UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41

origen biológico

mouse

Nivel de calidad

forma del anticuerpo

purified immunoglobulin

tipo de anticuerpo

primary antibodies

clon

NCM II 100, monoclonal

reactividad de especies

human

técnicas

immunocytochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable

isotipo

IgG1κ

Nº de acceso NCBI

Nº de acceso UniProt

Condiciones de envío

wet ice

modificación del objetivo postraduccional

unmodified

Información sobre el gen

human ... MYCN(4613)

Descripción general

The v-myc oncogene, initially identified in the MC29 avian retrovirus, causes myelocytomas, carcinomas, sarcomas and lymphomas, and belongs to a family of oncogenes conserved throughout evolution. In humans the family consists of five genes: c-myc, N-myc, R-myc, L-myc and B-myc. Amplification of the N-myc gene has been found in human neuroblastomas and cell lines. The extent of N-myc amplification correlates well with the stage of neuroblastoma disease. Immunological studies have shown that the human N-myc gene gives rise to at least two nuclear phosphoproteins that exhibit relatively short (30 min) half lives in vivo and exhibit DNA binding properties in vitro.

Inmunógeno

Recombinant protein corresponding to human N-Myc.

Aplicación

Immunofluorescence Analysis: A representative lot from an independent laboratory detected N-Myc in IMR5 cells (Ikegaki, N., et al. (1986). 83(16):5929-5933.).

Immunoprecipitation Analysis: A representative lot from an independent laboratory immunoprecipitated N-Myc in IP (Brondyk, W. H., et al. (1991). 6(7):1269-1276.).
Research Category
Epigenetics & Nuclear Function
Research Sub Category
Transcription Factors
Use Anti-N-Myc Antibody, clone NCM II 100 (mouse monoclonal antibody) validated in WB, IP, ICC to detect N-Myc also known as N-myc proto-oncogene protein, Class E basic helix-loop-helix protein 37, bHLHe37.

Calidad

Evaluated by Western Blot in IMR-32 cell lysate.

Western Blot Analysis: 0.5 µg/mL of this antibody detected N-Myc in 10 µg of IMR-32 cell lysate.

Descripción de destino

~55 kDa observed. Uniprot describes a molecular weight at ~50 kDa Uniprot states that this protein may be phosphorylated.

Forma física

Format: Purified
Protein G Purified
Purified mouse monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Almacenamiento y estabilidad

Stable for 1 year at 2-8°C from date of receipt.

Nota de análisis

Control
IMR-32 cell lysate

Otras notas

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Cláusula de descargo de responsabilidad

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Código de clase de almacenamiento

12 - Non Combustible Liquids

Clase de riesgo para el agua (WGK)

WGK 1

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Felix Schmitt-Hoffner et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(29), 3217-3228 (2021-06-11)
Clinical outcomes of patients with neuroblastoma range from spontaneous tumor regression to fatality. Hence, understanding the mechanisms that cause tumor progression is crucial for the treatment of patients. In this study, we show that FOXR2 activation identifies a subset of
Annie Beaudry et al.
Scientific reports, 13(1), 16443-16443 (2023-10-01)
Neuroblastoma, the most common type of pediatric extracranial solid tumor, causes 10% of childhood cancer deaths. Despite intensive multimodal treatment, the outcomes of high-risk neuroblastoma remain poor. We urgently need to develop new therapies with safe long-term toxicity profiles for
Patrick Sin-Chan et al.
Cancer cell, 36(1), 51-67 (2019-07-10)
Embryonal tumors with multilayered rosettes (ETMRs) are highly lethal infant brain cancers with characteristic amplification of Chr19q13.41 miRNA cluster (C19MC) and enrichment of pluripotency factor LIN28A. Here we investigated C19MC oncogenic mechanisms and discovered a C19MC-LIN28A-MYCN circuit fueled by multiple

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico